as of 11-17-2026 3:45pm EST
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.
| Founded: | 2016 | Country: | United Kingdom |
| Employees: | N/A | City: | ST. HELIER |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $3.01 | AVG Volume (30 days): | 4.0M |
| Analyst Decision: | Hold | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.61 | EPS Growth: | 68.75 |
| 52 Week Low/High: | $1.42 - $3.87 | Next Earning Date: | 11-03-2026 |
| Revenue: | $974,345,000 | Revenue Growth: | 0.61% |
| Revenue Growth (this year): | -12.87% | Revenue Growth (next year): | -6.52% |
| P/E Ratio: | -3.60 | Index: | |
| Free Cash Flow: | 365.3M | FCF Growth: | -3.85% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
SEC 8-K filings with transcript text
Nov 3, 2026 · 100% conf.
1D
-1.91%
$2.01
Act: +1.44%
5D
-3.33%
$1.98
20D
+0.33%
$2.06
2 ex991q32026earningsrelease.htm
Ex. 99.1 Q3 2026 Earnings Release
1
Clarivate Reports Third Quarter 2026 Results, Delivering Clear Path to Value Creation
— Improved recurring organic revenue growth driven by portfolio transformation
and AI-led innovation —
— Updates 2026 financial outlook following the divestiture of Life Sciences & Healthcare segment —
London, UK -- November 3, 2026 Clarivate Plc (NYSE: CLVT) (the “Company” or “Clarivate”), a leading
global provider of transformative intelligence, today reported results for the third quarter ended September 30,
2026.
Executive Commentary
Matti Shem Tov, Chief Executive Officer:
“Third quarter results continued to improve across key metrics, including organic recurring revenue growth and
the return to positive ACV growth in the Intellectual Property segment. We also achieved a major milestone with
the early close of the Life Sciences & Healthcare segment divestiture, positioning us for enhanced value creation
in our two market-leading segments, Academia & Government and Intellectual Property. The growing
commercial traction and customer validation from our AI-led innovation within A&G and IP give us confidence
in our ability to deliver on our commitments of accelerating sustained organic growth, expanding free cash flow
and reducing leverage.”
Michael Easton, Executive Vice President and Chief Financial Officer:
“We are seeing the benefits of disciplined execution across the business, with improving growth trends, strong
margins and continued free cash flow generation. Our focus remains on translating organic growth into
sustainable earnings and free cash flow, while maintaining a disciplined approach to capital allocation. Looking
ahead, we are well positioned to further strengthen our financial profile and enhance our financial flexibility.”
Third Quarter 2026 Results
Total revenues were $567.9 million, including the Life Sciences & Healthcare segment (“LS&H”), which was
divested on October 6, 2026, compared to total revenues of $623.1 million for the third quarter of 2025, primarily
due to inorganic disposals. Excluding LS&H, which is now presented as discontinued operations, total
revenues were $481.6 million, compared to total revenues of $530.3 million for the third quarter of 2025,
primarily due to inorganic disposals.
Organic revenues for continuing operations increased 0.4% as organic subscription growth of 1.5% and organic
re-occurring growth of 0.7% was partially offset by lower organic transactional revenues.
Organic ACV for continuing operations grew 1.8% compared to September 30, 2025, reflecting continued
progress toward a more sustainable, subscription-led revenue base.
Net loss, including LS&H, was $80.8 million, or $0.13 per diluted share, compared to a net loss of $28.3 million,
or $0.04 per diluted share, for the third quarter of 2025, driven by a $62.2 million non-cash LS&H goodwill
impairment charge. Adjusted net income, including LS&H, was $136.0 million, or $0.21 per diluted share,
compared to $119.3 million, or $0.18 per diluted share, for the third quarter of 2025. Adjusted EBITDA,
including LS&H, was $245.3 million, compared to Adjusted EBITDA of $252.4 million for the third quarter of
2025.
First Nine Months 2026 Results
Total revenues were $1,740.7 million, including the LS&H segment, compared to total revenues of $1,838.2
million, primarily due to inorganic disposals. Excluding the LS&H segment, which is now presented as
discontinued operations, total revenues were $1,472.4 million, compared to total revenues of $1,546.7 million
for the first nine months of 2025, primarily due to inorganic disposals.
Organic revenues for continuing operations increased 0.1%, as a 0.9% increase in organic recurring revenues
(subscription and re-occurring) was offset by lower organic transactional revenues.
2
Net loss, including LS&H, was $389.6 million, or $0.61 per diluted share, compared to a net loss of $204.2
million, or $0.30 per diluted share, for the first nine months of 2025, driven by a $283.9 million non-cash LS&H
goodwill impairment charge. Adjusted net income, including LS&H, was $378.4 million, or $0.59 per diluted
share, compared to $338.4 million, or $0.49 per diluted share, for the first nine months of 2025. Adjusted
EBITDA, including LS&H, was $733.7 million, compared to Adjusted EBITDA of $747.2 million for the first
nine months of 2025.
Clarivate, including LS&H, generated $399.0 million of operating cash flow and $233.1 million of free cash flow
during the first nine months of 2026.
Selected Financial Information
(In millions, except percentages and per share data),
(unaudited)
Three Months Ended
September 30,
Change
Nine Months Ended
September 30,
Change
2026
2025
$
%
2026
2025
$
%
Revenues, including discontinued operations
$567.9
$623.1
$(55.2)
(8.9)%
$1,740.7
$1,838.2
$(97.5)
(5.3)%
Revenues, continuing operations
$481.6
$
Jul 29, 2026 · 100% conf.
1D
-1.28%
$2.12
Act: -6.51%
5D
+7.01%
$2.30
Act: -9.77%
20D
+4.15%
$2.24
Transcript text not available. View on SEC.gov →
Apr 29, 2026
See how CLVT stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "CLVT Clarivate Plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.